| 查看: 264 | 回复: 1 | |||
| 当前主题已经存档。 | |||
abcd888898银虫 (正式写手)
|
[交流]
【转帖】Novo Nordisk receives approval for Victoza® in Japan
|
||
|
Novo Nordisk receives approval for Victoza® in Japan (20 January 2010) Read in PDF format Novo Nordisk receives approval for Victoza® in Japan Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Victoza® for the treatment of type 2 diabetes. Victoza® is the brand name for liraglutide, the first Glucagon-Like Peptide-1 (GLP-1) analogue approved in Japan, developed for the treatment of type 2 diabetes. Victoza® is indicated as monotherapy or as an add-on to sulphonylurea (SU) in people with type 2 diabetes. "The Japanese approval of Victoza® represents a major advancement in the treatment of type 2 diabetes and an important milestone for Novo Nordisk." says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "We are excited to pioneer the GLP-1 market in Japan, where we are convinced Victoza® will prove to be a valuable treatment option for people with type 2 diabetes. The clinical studies conducted in Japan showed Victoza® to provide superior glucose control with a low risk of hypoglycaemia." Novo Nordisk expects to launch Victoza® in Japan in the first half of 2010 upon completion of price negotiations. |
回复此楼» 猜你喜欢
药学求调剂，本科有论文，（材料、生物工程、生物与医药都可以）
已经有0人回复
-
（1055）求药学B区调剂
已经有0人回复
-
药物学论文润色/翻译怎么收费?
已经有287人回复
-
责编一直没有给动静 是凉了吗
已经有20人回复
-
河北医科大学药学相关专业接受调剂
已经有20人回复
-
【招聘】清华大学药学院钱锋教授课题组诚聘博士后
已经有1人回复
-
新版scifinder
已经有1人回复
-
安捷伦液相色谱柱与方法开发指南
已经有4人回复
-
2026申请考核博士自荐-蛋白质组学/AI/药物设计/AIDD/化学生物学
已经有1人回复
2楼2010-01-20 20:07:57